|
| Study ID | Characteristics |
|
| HALT-IT 2020 | Methods: |
| | Randomised controlled trial |
| | Participants: |
| | 12009 patients randomly assigned |
| | Inclusion criteria: |
| | GI bleed (upper or lower, however 89% were classified as upper GI bleeds) |
| | Mean age TXA group: 58 |
| | Mean age placebo group: 58 |
| | 7743 males |
| | 4266 females |
| | Interventions: |
| | TXA 1 g IV stat then 3 g infused over 24 hours |
| | Outcomes: |
| | Mortality: |
| | TXA group 222/5994 |
| | Placebo group 226/6015 |
| | Rebleeding: |
| | Not reported |
| | Adverse events MI, CVA, PE: |
| | TXA group 42/5994 |
| | Placebo group 46/6015 |
| | Need for surgery: |
| | TXA group 146/5994 |
| | Placebo group 158/6015 |
| | Transfusion required: |
| | TXA group 4076/5994 |
| | Placebo group 4129/6015 |
| Bagnenko 2011 | Methods: |
| | Randomised controlled trial |
| | Participants: |
| | 47 patients randomly assigned |
| | Inclusion criteria: |
| | Suspected upper GI bleed |
| | Mean age TXA group: 62 |
| | Mean age placebo group: 64 |
| | 29 males |
| | 18 females |
| | Interventions: |
| | TXA 10 mg IV/PO TDS for 3 days versus placebo |
| | Outcomes: |
| | Mortality: |
| | TXA group 1/22 |
| | Placebo group 3/25 |
| | Rebleeding: |
| | TXA group 2/22 |
| | Placebo group: 5/25 |
| | Adverse events: |
| | Not reported |
| | Need for surgery: |
| | TXA 1/22 |
| | Placebo 3/25 |
| | Transfusion required: |
| | TXA 14/22 |
| | Placebo 13/25 |
| Hawkey 2001 | Methods: |
| | Randomised controlled trial |
| | Participants: |
| | 206 patients randomly assigned. |
| | Inclusion criteria: |
| | Suspected upper GI bleed |
| | Mean age TXA group: 58 |
| | Mean age placebo group: 58 |
| | 126 males |
| | 80 females |
| | Interventions: |
| | TXA 2 g PO bolus then 1 g QDS for 4 days |
| | Outcomes: |
| | Mortality: |
| | TXA group 4/103 |
| | Placebo group 5/103 |
| | Rebleeding: |
| | TXA group 9/103 |
| | Placebo group: 10/103 |
| | Adverse events: |
| | No breakdown between intervention and control |
| | Need for surgery: |
| | TXA 5/103 |
| | Placebo 6/103 |
| | Transfusion required: |
| | TXA 58/103 |
| | Placebo 60/103 |
| Holstein 1987 | Methods: |
| | Randomised controlled trial |
| | Participants: |
| | 128 patients randomly assigned |
| | Inclusion criteria: |
| | Suspected upper GI bleed |
| | Mean age TXA group: 62 |
| | Mean age placebo group: 65 |
| | 90 males |
| | 38 females |
| | Interventions: |
| | TXA 1 g every 4 hours for 24 hours then 1.5 g PO QDS for 5 days |
| | Outcomes: |
| | Mortality: |
| | TXA group 2/128 |
| | Placebo group 4/128 |
| | Rebleeding: |
| | TXA group 10/128 |
| | Placebo group 19/128 |
| | Adverse events MI, CVA, PE: |
| | TXA group 0/128 |
| | Placebo group 2/128 |
| | Need for surgery: |
| | TXA group 3/128 |
| | Placebo group 15/128 |
| | Transfusion required: |
| | TXA group 47/128 |
| | Placebo group 54/128 |
| Bergqvist 1980 | Methods: |
| | Randomised controlled trial |
| | Participants: |
| | 50 patients randomly assigned |
| | Inclusion criteria: |
| | Suspected upper GI bleed |
| | Mean age TXA group: 61 |
| | Mean age placebo group: 58 |
| | 40 males |
| | 10 females |
| | Interventions: |
| | TXA 2 g PO 4 hourly for two days |
| | Outcomes: |
| | Mortality: |
| | TXA group 3/25 |
| | Placebo group 5/25 |
| | Rebleeding: |
| | Not reported |
| | Adverse events MI, CVA, PE: |
| | Not reported |
| | Need for surgery: |
| | TXA group 7/25 |
| | Placebo group 7/25 |
| | Transfusion required: |
| | Not reported |
|
| Engquist 1979 | Methods: |
| | Randomised controlled trial |
| | Participants: |
| | 204 patients randomly assigned |
| | Inclusion criteria: |
| | Suspected upper GI bleed |
| | Mean age TXA group: 59 |
| | Mean age placebo group: 56 |
| | 159 males |
| | 45 females |
| | Interventions: |
| | TXA 1 g IV 4 hourly for 1 day then 1.5 g PO QDS for 6 days |
| | Outcomes: |
| | Mortality: |
| | TXA group 11/102 |
| | Placebo group 12/102 |
| | Rebleeding: |
| | TXA group 23/102 |
| | Placebo group 29/102 |
| | Adverse events MI, CVA, PE: |
| | TXA group 4/102 |
| | Placebo group 2/102 |
| | Need for surgery: |
| | TXA group 10/102 |
| | Placebo group 18/102 |
| | Transfusion required: |
| | Not reported |
| Biggs 1976 | Methods: |
| | Randomised controlled trial |
| | Participants: |
| | 200 patients randomly assigned |
| | Inclusion criteria: |
| | Suspected upper GI bleed |
| | Mean age TXA group: not reported |
| | Mean age placebo group: not reported |
| | 156 males |
| | 44 females |
| | Interventions: |
| | TXA 1 g IV stat then 1 g PO QDS on day 1, |
| | Then 1 g QDS for 4 days |
| | Outcomes: |
| | Mortality: |
| | TXA group 2/103 |
| | Placebo group 4/97 |
| | Rebleeding: |
| | TXA group 7/103 |
| | Placebo group 21/97 |
| | Adverse events MI, CVA, PE: |
| | Not reported |
| | Need for surgery: |
| | TXA group 7/103 |
| | Placebo group 21/97 |
| | Transfusion required: |
| | TXA group 77/103 |
| | Placebo group 71/97 |
|
| Cormack 1973 | Methods: |
| | Randomised controlled trial |
| | Participants: |
| | 150 patients randomly assigned |
| | Inclusion criteria: |
| | Suspected upper GI bleed |
| | Mean age TXA group: not reported |
| | Mean age placebo group: not reported |
| | 101 males |
| | 49 females |
| | Interventions: |
| | TXA 1.5 g QDS for 7 days |
| | Outcomes: |
| | Mortality: |
| | TXA group 3/76 |
| | Placebo group 3/74 |
| | Rebleeding: |
| | TXA group 8/76 |
| | Placebo group 11/74 |
| | Adverse events MI, CVA, PE: |
| | Not reported |
| | Need for surgery: |
| | Not reported |
| | Transfusion required: |
| | TXA group 68/76 |
| | Placebo group 63/74 |
|
